Vitamin D gets the headlines. Omega-3s get the influencers. Magnesium runs over 300 enzymatic reactions in your body and roughly half of Americans are not getting enough of it.

Energy production. Muscle contraction. Blood pressure regulation. Blood sugar control. Bone density. Sleep. Nerve transmission. Heart rhythm. Your body runs all of these on magnesium. When you are low, all of them degrade, slowly, invisibly, and in ways that are easy to blame on aging.

This is not a deficiency that shows up clearly on your standard blood work. Serum magnesium is tightly regulated. It drops last. You can be depleted in tissue and muscle while your lab results look normal.

Most people go undiagnosed. Most supplements prescribed to fix it barely absorb. And the supplement industry has done an excellent job of obscuring which form actually works.

Let’s run it through the filter.

Magnesium depletion accelerates with age for three compounding reasons. First, dietary intake declines, processed food dominates the American diet and virtually all processing removes magnesium. Second, gut absorption decreases with age. Third, several medications common in the 40-70 demographic actively deplete magnesium: proton pump inhibitors (PPIs), diuretics, and metformin all accelerate magnesium loss.

The consequences compound quietly. Low magnesium increases insulin resistance, raising the risk of type 2 diabetes. It impairs muscle relaxation, contributing to cramps and weakness. It disrupts sleep architecture. It raises blood pressure via impaired vasodilation. It increases cardiovascular risk. It reduces bone density by interfering with calcium metabolism.

None of these present as “magnesium deficiency.” They present as middle age.

Yes. The evidence base is deep and consistent across multiple outcome domains.

CARDIOVASCULAR AND BLOOD PRESSURE: Strong RCT evidence. A 2025 meta-analysis published in Hypertension (American Heart Association) analyzed 38 randomized controlled trials involving 2,709 participants. Magnesium supplementation reduced systolic blood pressure by 2.81 mmHg and diastolic by 2.05 mmHg compared to placebo. Effect was strongest in hypertensive individuals and those with lower baseline magnesium. A 2024 umbrella meta-analysis confirmed the blood pressure reduction across multiple prior meta-analyses.

SLEEP: Real, strongest in those who are deficient. A 2021 systematic review and meta-analysis found that magnesium supplementation reduced sleep onset latency by 17 minutes compared to placebo in older adults with insomnia. A 2024 randomized controlled trial (bisglycinate form) confirmed improvements in sleep quality and mood in adults with poor sleep. Key nuance: effect is most pronounced in those with low magnesium status. If you are replete, the sleep benefit is smaller.

INSULIN RESISTANCE AND METABOLIC HEALTH: Consistent association evidence. Magnesium deficiency is linked to impaired glucose metabolism and increased insulin resistance. A 2024 comprehensive review (Cureus) confirms the mechanistic relationship: magnesium is required for insulin receptor function and glucose transporter activation. Supplementation has shown improvements in insulin sensitivity in individuals with low magnesium levels and metabolic syndrome.

MUSCLE FUNCTION AND BONE DENSITY: Well-established mechanistic and clinical evidence. Magnesium is required for muscle relaxation (calcium-magnesium antagonism), ATP production, and bone mineralization. Low magnesium is consistently associated with muscle cramps, weakness, and reduced bone density. The NIH Office of Dietary Supplements confirms the established role of magnesium in skeletal integrity and muscular function.

The blood pressure reduction, 2.81 mmHg systolic, is real but modest. It is not a replacement for antihypertensive medication in people who need it. The sleep evidence is strongest in older adults with documented low magnesium status; studies in well-nourished, replete populations show weaker and less consistent effects. Most trials are short-term, typically 8 to 12 weeks, so long-term data on all outcomes remains limited. And while the association between magnesium deficiency and insulin resistance is well-established, RCT evidence that supplementation alone reverses type 2 diabetes is not.

The MED Report position: the evidence is strongest as a deficiency correction, not as a performance enhancer. If you are replete, the benefits are smaller. If you are deficient, and the odds say roughly half of you are, the evidence across cardiovascular, sleep, and metabolic outcomes is consistent and clinically meaningful.

This is the most important practical information in this edition, and the information most supplement labels actively obscure.

Not all magnesium forms absorb equally. The cheapest and most common form, magnesium oxide, has approximately 4% bioavailability. It works primarily as a laxative. It does not meaningfully raise tissue magnesium levels.

The evidence-supported forms for systemic magnesium repletion:

Magnesium oxide, magnesium sulfate, and most cheap “magnesium” products: poor absorption, not recommended for deficiency correction.

Rule of thumb: if the label says “magnesium” without specifying the form, or says “magnesium oxide,” put it back.

At $10-20 per month for magnesium glycinate, this is one of the most cost-effective interventions available for the 40-70 demographic. The outcomes it supports, cardiovascular health, sleep, blood sugar regulation, muscle function, bone density, are exactly the outcomes that deteriorate fastest in this age group.

The ROI calculation is straightforward: a mineral your body requires for over 300 processes, which half the population is not getting enough of, which standard blood tests do not reliably detect, which has a clean evidence base across multiple outcome domains, and which costs less than a single cup of coffee per day.

The only reason most people are not taking it is that nobody has told them clearly which form to buy.

This recommendation is for otherwise healthy adults.

Magnesium is not a trending supplement. It does not have influencer backing. It cannot be meaningfully differentiated by brand because the molecule is a molecule. The business case for a magnesium marketing campaign does not exist, especially when the most important thing to communicate is “buy the glycinate form, not the version we’re selling you.”

The result is a population that is broadly deficient in a mineral essential to hundreds of bodily processes, being sold ineffective forms of that mineral at high margins, while the evidence quietly accumulates in journals nobody is reading.

That gap is exactly what this newsletter exists to close.

Subscribe free — one edition in your inbox every Wednesday. No spam. No conflicts of interest. Any future sponsorships will be clearly disclosed and personally vetted.

After subscribing, check your junk/spam folder for the confirmation email and mark it as ‘Not Spam’ to ensure delivery.